Beverly L. Davidson

Sep 18, 2024 | biorxiv.org | Sakshi Arora |Jonathan Lang |Beverly L. Davidson |Emily O'Driscoll

AbstractRecombinant adeno-associated virus (rAAV) vectors are an effective and well-established tool in the growing gene therapy field, with five approved AAV-mediated gene therapies already on the market and numerous more in clinical trials. However, manufacturing rAAV vectors is an expensive, timely, and labor-intensive process that limits the commercial use of AAV-mediated gene therapies.

Aug 3, 2023 | medscape.com | Beverly L. Davidson

closePlease confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log outCancel Collectively, affecting between 263 to 446 million individuals worldwide, only ~5% of rare diseases have an approved treatment option.